Literature DB >> 15812834

Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma.

Shi-Xiong Liang1, Xiao-Dong Zhu, Hai-Jie Lu, Chao-Yang Pan, Fu-Xiang Li, Qi-Fang Huang, An-Yu Wang, Long Chen, Xiao-Long Fu, Guo-Liang Jiang.   

Abstract

BACKGROUND: The purpose of the current study was to evaluate the tolerance and efficacy of hypofractionated three-dimensional conformal radiotherapy (3DCRT) with or without transarterial chemoembolization (TACE) for technically unresectable or medically inoperable primary liver carcinoma (PLC).
METHODS: Between April 1999 and August 2003, 128 patients with a clinical diagnosis of PLC received hypofractionated 3DCRT at Cancer Hospital, Guangxi Medical University. Both hypofractionated 3DCRT and TACE were used to treat 48 of these 128 patients. Liver cirrhosis of Child-Pugh Grade A was found in 108 patients, and Grade B was found in 20 patients. The mean gross tumor volume (GTV) was 459 +/- 430 cm3. A mean total irradiation dose of 53.6 +/- 6.6 Gy was delivered at an average fraction of 4.88 +/- 0.47 Gy, 3 times a week using 8-MV photons.
RESULTS: The median follow-up time after 3DCRT was 12 months (range, 2-56 mos.). The immediate response rate was 55%. The overall survival rates at 1, 2, and 3 years were 65%, 43%, and 33%, respectively, with a median survival of 20 months (range, 7-31 mos.). Radiation Therapy Oncology Group (RTOG) Grade 2 acute gastrointestinal complications developed in 8 patients, whereas 4 patients developed Grade 3 late gastrointestinal complications. Radiation-induced liver disease (RILD) developed in 19 (15%) patients, of which 12 had Child-Pugh Grade B liver cirrhosis, and 7 had Grade A. GTV and associated liver cirrhosis were identified by Cox regression analysis as independent predictors for survival (P = 0.044 and 0.015).
CONCLUSIONS: Hypofractionated 3DCRT is effective in carefully selected patients with PLC. Gastrointestinal complications and RILD were the most distinct complications.

Entities:  

Mesh:

Year:  2005        PMID: 15812834     DOI: 10.1002/cncr.21012

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

Review 1.  Hepatic radiation toxicity: avoidance and amelioration.

Authors:  Chandan Guha; Brian D Kavanagh
Journal:  Semin Radiat Oncol       Date:  2011-10       Impact factor: 5.934

Review 2.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 3.  Nonsurgical multidisciplinary approach for recurrent hepatocellular carcinoma after surgical resection.

Authors:  Kang Mo Kim
Journal:  Hepat Oncol       Date:  2015-01-12

4.  Curative effect of stereotactic body radiotherapy on hepatic hilar carcinoma.

Authors:  Ya-Zheng Dang; Shi-Gao Huang; Wan-Ling Lu; Fa-Wei Wu; Qian-Yun Wang
Journal:  Mol Clin Oncol       Date:  2014-08-20

Review 5.  Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience.

Authors:  Matthew M Yeh; Raymond S Yeung; Smith Apisarnthanarax; Renuka Bhattacharya; Carlos Cuevas; William P Harris; Tony Lim Kiat Hon; Siddharth A Padia; James O Park; Kevin M Riggle; Sayed S Daoud
Journal:  World J Hepatol       Date:  2015-06-18

6.  Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Sung Uk Lee; Joong-Won Park; Tae Hyun Kim; Yeon-Joo Kim; Sang Myung Woo; Young-Hwan Koh; Woo Jin Lee; Sang-Jae Park; Dae Yong Kim; Chang-Min Kim
Journal:  Strahlenther Onkol       Date:  2014-03-04       Impact factor: 3.621

7.  Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.

Authors:  Jian-Dong Zhao; Jin Liu; Zhi-Gang Ren; Ke Gu; Zhen-Hua Zhou; Wen-Tao Li; Zhen Chen; Zhi-Yong Xu; Lu-Ming Liu; Guo-Liang Jiang
Journal:  Radiat Oncol       Date:  2010-02-12       Impact factor: 3.481

8.  Prognostic index for portal vein tumor thrombosis in patients with hepatocellular carcinoma treated with radiation therapy.

Authors:  Jeong Il Yu; Hee Chul Park; Do Hoon Lim; Won Park; Byung Chul Yoo; Seung Woon Paik; Kwang Cheol Koh; Joon Hyuk Lee
Journal:  J Korean Med Sci       Date:  2011-07-27       Impact factor: 2.153

9.  Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults.

Authors:  Liming Lu; Jingchun Zeng; Zehuai Wen; Chunzhi Tang; Nenggui Xu
Journal:  Cochrane Database Syst Rev       Date:  2019-02-16

10.  Treatment outcomes of helical intensity-modulated radiotherapy for unresectable hepatocellular carcinoma.

Authors:  Moonkyoo Kong; Seong Eon Hong; Woo Suk Choi; Jinhyun Choi; Youngkyong Kim
Journal:  Gut Liver       Date:  2013-04-09       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.